These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 11586419)

  • 21. In vivo models of multiple myeloma (MM).
    Sanchez E; Chen H; Berenson JR
    Biochem Pharmacol; 2014 Jun; 89(3):313-20. PubMed ID: 24704250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation.
    Binsfeld M; Beguin Y; Belle L; Otjacques E; Hannon M; Briquet A; Heusschen R; Drion P; Zilberberg J; Bogen B; Baron F; Caers J
    PLoS One; 2014; 9(11):e113764. PubMed ID: 25415267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adoptive B-cell transfer mouse model of human myeloma.
    Tompkins VS; Rosean TR; Holman CJ; DeHoedt C; Olivier AK; Duncan KM; Jing X; Foor SD; Acevedo MR; Walsh SA; Tricot G; Zhan F; Janz S
    Leukemia; 2016 Apr; 30(4):962-6. PubMed ID: 26202932
    [No Abstract]   [Full Text] [Related]  

  • 24. MOPC-315 murine plasmacytoma as a model anticancer screen for human multiple myeloma.
    Valeriote F; Grates H
    J Natl Cancer Inst; 1986 Jan; 76(1):61-5. PubMed ID: 3455743
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumorigenicity and intracisternal A-particle expression of hybrids between murine myeloma and lymphocytes.
    Giacomoni D
    Cancer Res; 1979 Nov; 39(11):4481-4. PubMed ID: 498079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma.
    Sanchez E; Gillespie A; Tang G; Ferros M; Harutyunyan NM; Vardanyan S; Gottlieb J; Li M; Wang CS; Chen H; Berenson JR
    Clin Cancer Res; 2016 Jul; 22(13):3383-97. PubMed ID: 26960399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The treatment of plasma cell myeloma.
    Bergsagel DE
    Br J Haematol; 1976 Aug; 33(4):443-9. PubMed ID: 795453
    [No Abstract]   [Full Text] [Related]  

  • 28. Role of interleukin-6 in the pathogenesis of murine plasmacytoma and human multiple myeloma.
    Pattengale PK
    Am J Pathol; 1997 Sep; 151(3):647-9. PubMed ID: 9284811
    [No Abstract]   [Full Text] [Related]  

  • 29. Evaluation of a cooperative group human myeloma protocol using the MOPC 104E myeloma model.
    Hiramoto R; Ghanta V; Durant JR
    Cancer Res; 1975 May; 35(5):1309-13. PubMed ID: 1120314
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effects and mechanisms of recombinant human erythropoietin in treating multiple myeloma in murine mice].
    Zhou MY; Yu L; Meng WT; Xu CG
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 Sep; 41(5):797-802. PubMed ID: 21302444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Host range and oncogenicity studies of the murine myeloma MOPC-315 type-C retrovirus.
    Gazit A; Guthmann D; Yaniv A
    Int J Cancer; 1981 Mar; 27(3):335-40. PubMed ID: 6270016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mouse myeloma. A model for studies of cell kinetics.
    Bergsagel DE; Ogawa M; Librach SL
    Arch Intern Med; 1975 Jan; 135(1):109-13. PubMed ID: 1111459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted idiotype-fusion DNA vaccines for human multiple myeloma: preclinical testing.
    Frøyland M; Ruffini PA; Thompson KM; Gedde-Dahl T; Fredriksen AB; Bogen B
    Eur J Haematol; 2011 May; 86(5):385-95. PubMed ID: 21332794
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disseminated growth of a human multiple myeloma cell line in mice with severe combined immunodeficiency disease.
    Huang YW; Richardson JA; Tong AW; Zhang BQ; Stone MJ; Vitetta ES
    Cancer Res; 1993 Mar; 53(6):1392-6. PubMed ID: 8443818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Experimental murine amyloidosis: a model system for studying amyloid formation.
    Baumal R; Wilson B; Pass E
    Can Med Assoc J; 1975 Sep; 113(6):512-6. PubMed ID: 1080430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonirradiated NOD/SCID-human chimeric animal model for primary human multiple myeloma: a potential in vivo culture system.
    Huang SY; Tien HF; Su FH; Hsu SM
    Am J Pathol; 2004 Feb; 164(2):747-56. PubMed ID: 14742278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myeloma proteins from NZB and BALB/c mice: structural and functional differences.
    Loh E; Black B; Riblet R; Weigert M; Hood JM; Hood L
    Proc Natl Acad Sci U S A; 1979 Mar; 76(3):1395-9. PubMed ID: 108679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Idiotype protein-pulsed dendritic cells produce strong anti-myeloma effects after syngeneic stem cell transplantation in mice.
    Zeis M; Frenzke H; Schmitz N; Uharek L; Steinmann J
    Bone Marrow Transplant; 2002 Feb; 29(3):213-21. PubMed ID: 11859393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic effects of idiotype vaccination can be enhanced by the combination of granulocyte-macrophage colony-stimulating factor and interleukin 2 in a myeloma model.
    Stritzke J; Zunkel T; Steinmann J; Schmitz N; Uharek L; Zeis M
    Br J Haematol; 2003 Jan; 120(1):27-35. PubMed ID: 12492573
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma.
    Oyajobi BO; Mundy GR
    Cancer; 2003 Feb; 97(3 Suppl):813-7. PubMed ID: 12548580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.